MARKER THERAPEUTICS, INC. Induced Conversion of Convertible Debt Expense
MARKER THERAPEUTICS, INC. (MRKR) reported Induced Conversion of Convertible Debt Expense of $70.31 thousand for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2016-08-15
- MARKER THERAPEUTICS, INC. induced conversion of convertible debt expense for the quarter ending 2016-06-30 was $70.31K.
| Period end | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month |
|---|---|---|
| 2016-06-30 | $70.31K 10-Q · filed 2016-08-15 | $70.31K 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |